Insights
Current myocarditis classification schemes lack perfection. Standardizing with the Dallas histologic criteria and conducting multicenter trials are crucial for understanding and treating this condition effectively.
Area of Science:
- Cardiology
- Pathology
- Medical Research
Background:
- Existing classification schemes for myocarditis are imperfect for clinical and research applications.
- The Dallas criteria offer a histology-based approach for standardization.
Purpose of the Study:
- To advocate for the adoption of the Dallas criteria to standardize myocarditis classification.
- To highlight the need for multicenter randomized trials to determine optimal treatment, particularly immunosuppressive therapy.
- To emphasize the importance of standard nomenclature for future research.
Main Methods:
- Review and discussion of existing myocarditis classification systems.
- Proposal for the adoption of the Dallas criteria for histological classification.
- Call for large-scale, multicenter randomized trials for treatment optimization.
Main Results:
- The Dallas criteria, while histology-based, are recommended for standardization.
- Optimal immunosuppressive therapy for myocarditis remains undefined.
- Multicenter randomized trials are necessary to establish effective treatments.
Conclusions:
- Standardization of myocarditis classification is essential for research progress.
- Future research should focus on defining clinical correlates and prognostic utility of histological categories.
- A hybrid clinical-pathologic classification scheme is desired for improved diagnosis, prognosis, and treatment prediction.
Abstract:
In closing, we can only note that none of the classification schemes for myocarditis has been perfect for clinicians, pathologists, and researchers alike. The definition and classification protocol offered by the "Dallas" group is based solely on histology, but we urge its use by physicians and other researchers as a means of imposing some standardization on the study of myocarditis. The question of optimum treatment, particularly immunosuppressive therapy, has never been definitively answered, but it is now clear that a large, multicenter randomized trial is the only proper method to search for such an answer. Standard nomenclature is a prerequisite for this study. In the meantime, the clinical correlates and prognostic utility of these histologic categories may be defined; these morphologic groupings will probably be shown to be clinically heterogeneous. In the end, we hope a hybrid clinical-pathologic scheme for the diagnosis and classification of myocarditis will be forged. Such a protocol, ideally, will allow the correlation of structure with function and also reliably predict clinical behavior and response to treatment so that someday we may be able to both counsel and cure persons with myocarditis.
More Related Videos
12:24Noninvasive Assessment of Cardiac Abnormalities in Experimental Autoimmune Myocarditis by Magnetic Resonance Microscopy Imaging in the Mouse
Published on: June 20, 2014
09:16Isolation and Characterization of Cardiac Mesenchymal Stromal Cells from Endomyocardial Bioptic Samples of Arrhythmogenic Cardiomyopathy Patients
Published on: February 28, 2018
Related Concept Videos
Myasthenia Gravis: Diagnostic Tests
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
Myocarditis I: Introduction
Myocarditis II: Clinical Features and Diagnostic Tests
Myocarditis III: Medical Management
Acute Coronary Syndrome III: Diagnostic Studies
Cardiomyopathy IV: Restrictive Cardiomyopathy
